Kelsey Goodwin
Stock Analyst at Guggenheim
(0.91)
# 2,789
Out of 4,413 analysts
11
Total ratings
42.86%
Success rate
-12.7%
Average return
Main Sectors:
Top Industries:
6 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NUVL Nuvalent | Assumes: Buy | $99 | $70.65 | +40.13% | 1 | Feb 28, 2024 | |
| TSVT 2seventy bio | Downgrades: Neutral | n/a | $4.60 | - | 4 | Sep 13, 2023 | |
| ACLX Arcellx | Maintains: Buy | n/a | $52.18 | - | 3 | Jun 20, 2023 | |
| LEGN Legend Biotech | Initiates: Neutral | n/a | $43.98 | - | 1 | Oct 31, 2022 | |
| IOVA Iovance Biotherapeutics | Initiates: Neutral | n/a | $12.50 | - | 1 | Oct 31, 2022 | |
| IPSC Century Therapeutics | Initiates: Buy | $15 | $3.04 | +393.42% | 1 | Oct 31, 2022 |
Nuvalent
Feb 28, 2024
Assumes: Buy
Price Target: $99
Current: $70.65
Upside: +40.13%
2seventy bio
Sep 13, 2023
Downgrades: Neutral
Price Target: n/a
Current: $4.60
Upside: -
Arcellx
Jun 20, 2023
Maintains: Buy
Price Target: n/a
Current: $52.18
Upside: -
Legend Biotech
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $43.98
Upside: -
Iovance Biotherapeutics
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $12.50
Upside: -
Century Therapeutics
Oct 31, 2022
Initiates: Buy
Price Target: $15
Current: $3.04
Upside: +393.42%